AMT-253 in Patients With Selected Advanced Solid Tumours

Summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

Timeline

Start

2023-11-06

Primary completion

2026-09-30

Completion

2026-12-30

Drugs

Indications